Skip to main content
TipRanks
Go Ultimate75% OFF

Greenwich LifeSciences (GLSI) AI Stock Analysis

454 Followers
GLSI

Greenwich LifeSciences

(NASDAQ:GLSI)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Negative Factors

Greenwich LifeSciences (GLSI) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%300%GLSI+135.60%SPY+8.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$290.48M
Dividend Yield
―
Average Volume (3M)
156.20K
Price to Earnings (P/E)
-12.1
Beta (1Y)
1.95
Revenue Growth
―
EPS Growth
-9.87%
Country
US
Employees
13
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Greenwich LifeSciences Business Overview & Revenue Model

Company Description

Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its fla...

Greenwich LifeSciences Risk Analysis

Greenwich LifeSciences disclosed 72 risk factors in its most recent earnings report. Greenwich LifeSciences reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.We may hold cash and cash equivalents at various foreign subsidiaries and in countries outside of the US that may not be readily available to meet cash requirements.Q4, 2023
2.In the clinical trials using GP2, improper intradermal injections or poor HLA binding by GP2 may potentially jeopardize the outcome of the trials.Q4, 2023
3.Data from our clinical trials that we announce or publish from time to time may change as more patient data become available either through long-term patient follow-up and/or as such data is audited and verified, which could result in material changes to clinical and safety profiles for our products.Q4, 2023

Greenwich LifeSciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GLSI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CGENCGEN73Outperform$178.09M4.8339.30%―999.97%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NKTXNKTX43Neutral$80.31M-0.65-48.58%――-24.79%
SKYESKYE42Neutral$3.48M-0.10-503.95%――26.40%
STTKSTTK42Neutral$463.38M-8.92-46.46%―-100.00%50.26%
MOLNMOLN39Underperform$103.37M-1.60-79.25%――11.22%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%GLSICGENSKYENKTXSTTKMOLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GLSI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GLSIGreenwich Lifesciences, Inc.19.7911.94152.10%
CGENCompugen1.880.2918.24%
SKYESkye Bioscience, Inc.0.79-9.61-92.44%
NKTXNkarta, Inc.1.12-0.67-37.43%
STTKShattuck Labs, Inc.4.552.49120.87%
MOLNMolecular Partners Ag2.60-1.40-34.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.